HDM201 + cytarabine + anthracycline

HDM201 + cytarabine + anthracycline is an investigational combination regimen under clinical testing, primarily for the treatment of hematological malignancies such as acute myeloid leukemia (AML). HDM201 (also known as siremadlin) is a potent, selective inhibitor of the p53–MDM2 interaction, aiming to reactivate the tumor suppressor function of wild-type p53, leading to cell cycle arrest and apoptosis in cancer cells. Cytarabine is a nucleoside analog that inhibits DNA synthesis, commonly used in leukemia chemotherapy. Anthracyclines are a class of anti-tumor antibiotics (such as daunorubicin or doxorubicin) that bind DNA, inhibit topoisomerase II, and generate free radicals, leading to apoptosis of cancer cells. The combination exploits non-overlapping mechanisms of action to enhance anti-leukemic activity: HDM201 reactivates p53 signaling, cytarabine inhibits DNA synthesis, and anthracyclines damage DNA and disrupt cell replication.

Other names

siremadlin + cytarabine + anthracycline